Canada Objects To America’s Announcement To Import Drugs From Its Northern Neighbor
Source:Thailand Medical News Dec 20, 2019 5 years, 3 days, 22 hours, 39 minutes ago
President Trump's administration unveiled a plan Wednesday to allow imports of lower-priced prescription
drugs from Canada and other countries, but it was opposed by Ottawa, which said the scheme threatened its own
medicine stocks.
Typically, Americans spend an average of $1,200 on prescription
drugs per year, more than in any other country in the world and the US president has made driving down costs a top priority for next year's election.
Health Secretary Alex Azar told
Thailand Medical News via a press statement, "The president has recognized the opportunity to lower costs for American patients through safe importation."
However a spokesman for Canada's health minister Patty Hajdu said in a press statement, "Our government will protect our supply of and access to medication that Canadians rely on. Our message remains firm: We share the goal of ensuring people can get and afford the
medication they need but these measures will not have any significant impact on prices or access for Americans. We remain firmly focused on ensuring Canadians can access the medication they need."
The opposition by Canada could present a major challenge to Trump's plan, especially if Ottawa passes a law banning the practice, known in economics as "parallel trading."
America is alone among advanced countries in allowing manufacturers to set their own prices, rather than having to negotiate with national health insurance systems, one of several factors that have led to spiraling costs.
For example,the price of insulin, a life-saving medicine used to treat diabetes, has more than tripled over the past decade, forcing many uninsured patients to ration their doses, smuggle it in from Canada or Mexico, or even choose between treatment and other basic expenses such as rent.
The
pharma issue has come to the fore in 2020 presidential election campaign, with all the leading Democratic contenders vowing to repeal the law preventing the government from negotiating with the
drug manufacturers. Senator Bernie Sanders has also led bus trips across the border from his home state Vermont to buy lower cost insulin in order to highlight the problem.
Health Secretary Azar proposed rules Wednesday indicating two pathways to formalize the president's plan, which was first outlined in July. Under the first, US states would be allowed to propose importation programs for
drugs already authorized in Canada, subject to approval by the US Food and Drug Administration.
However, the program would not include
biological drugs ones made from large or live molecules meaning medications such as insulin would be excluded.
The other pathway would allow US pharmaceutical companies to import
drugs originally manufactured and intended to be marketed abroad, including
biological drugs. The measure, Azar said, would allow
drug companies to "bring that same product in the United States to basically compete against your own produc
t, but at a lower list price."
Both pathways are subject to comment periods before they are finalized, but there is no firm timeline for implementation.
Canada has previously expressed reservations. Last month, its acting ambassador to the United States Kristin Hillman cited a recent study that estimated if 40 percent of US prescriptions were filled from Canada, the Canadian
drug supply would run out in 118 days.
The import plan could also face legal challenges from the
pharmaceutical industry, which denounced it as "dangerous" when it was first previewed, arguing patients could be exposed to substandard or counterfeit
drugs.
CEO of Pharmaceutical Research and Manufacturers of America, Stephen Ubl, urged the government to instead focus on policies that lower patients' out-of-pocket
medicine costs, the portion that insurance companies do not cover.
The
pharma industry argues that pushing down prices would undermine innovation, but critics say rising expenses are not only linked to research and development.
A Harvard Medical School 2016 study blamed factors such as the US patent system, which grants makers "government-protected monopolies" through market exclusivity that lasts years before generics can enter the market, and can be extended through "trivial" changes to patented molecules.
Pharma makers have also been able to sidestep competition by offering settlements that pay generic companies to delay their lower-cost alternatives, known as "pay for delay" deals.
While in the European Union, where parallel trading of medicine is legal, it has been blamed for creating
drug shortages in countries like Greece and Italy where traders buy "low" and re-sell to countries that have higher prices, such as the United Kingdom and Germany.
